Literature DB >> 8180250

Hepatic carnitine palmitoyltransferase-I has two independent inhibitory binding sites for regulation of fatty acid oxidation.

K Kashfi1, R L Mynatt, G A Cook.   

Abstract

Partial proteolysis of carnitine palmitoyltransferase (CPT-I) in intact mitochondria results in greatly diminished sensitivity to inhibition by its physiological inhibitor, malonyl-CoA, but inhibition by succinyl-CoA and methylmalonyl-CoA was affected to a lesser extent, whereas inhibition by coenzyme A, acetyl-CoA, and propionyl-CoA was not affected at all by proteinase treatment. These data suggested that inhibitors that are coenzyme A esters of short-chain dicarboxylic acids bind to a regulatory malonyl-CoA binding site located on the cytoplasmic face of the mitochondrial outer membrane while coenzyme A esters of monocarboxylic acids and free coenzyme A act at the active site in the mitochondrial intermembrane space. All inhibitors whose potency was altered by proteinase action provided protection against proteinases, whereas other inhibitors did not. Preincubation with the substrates carnitine, palmitoyl-CoA, or coenzyme A prior to proteolysis showed no protective effects against the loss of inhibition or loss of activity; however, preincubation with these substrates enhanced proteinase effects to more seriously diminish activity and inhibition by malonyl-CoA. Proteinases were also found to act on purified mitochondrial outer membranes to reduce inhibition by malonyl-CoA with little effect on activity. Using these outer membrane preparations it was found that the very potent inhibition of CPT-I by the active-site-directed substrate analog (+)-hemipalmitoylcarnitinium was not altered by proteinase treatment; however, inhibition by the malonyl-CoA analog Ro 25-0187, which is a more potent inhibitor than malonyl-CoA, was drastically reduced by proteinase treatment of mitochondrial outer membranes, confirming the different locations for the malonyl-CoA site and the active site. Coenzyme A and malonyl-CoA both act as competitive inhibitors with respect to the acyl-CoA substrate, but coenzyme A lacks cooperative effects seen with malonyl-CoA. For ligand binding to the malonyl-CoA regulatory site, there appears to be a requirement for two carbonyl groups in close juxtaposition, but there is apparently no requirement for the coenzyme A moiety per se. Current evidence, including the recently deduced primary structure for CPT-I, favors the hypothesis that (a) inhibitors of CPT-I may act at two distinct sites, (b) malonyl-CoA binds primarily to a regulatory site that is distinct from the active site of carnitine palmitoyltransferase-I, and (c) the two inhibitory sites are located on opposite sides of the mitochondrial outer membrane.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180250     DOI: 10.1016/0005-2760(94)90259-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues.

Authors:  M Morillas; J Clotet; B Rubí; D Serra; J Ariño; F G Hegardt; G Asins
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Topology of carnitine palmitoyltransferase I in the mitochondrial outer membrane.

Authors:  F Fraser; C G Corstorphine; V A Zammit
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

3.  Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.

Authors:  P T Clayton; S Eaton; A Aynsley-Green; M Edginton; K Hussain; S Krywawych; V Datta; H E Malingre; R Berger; I E van den Berg
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 4.  Differential regulation in the heart of mitochondrial carnitine palmitoyltransferase-I muscle and liver isoforms.

Authors:  E A Park; G A Cook
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  A comprehensive analysis of myocardial substrate preference emphasizes the need for a synchronized fluxomic/metabolomic research design.

Authors:  Mukundan Ragavan; Alexander Kirpich; Xiaorong Fu; Shawn C Burgess; Lauren M McIntyre; Matthew E Merritt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-04-14       Impact factor: 4.733

6.  Roles of the N- and C-terminal domains of carnitine palmitoyltransferase I isoforms in malonyl-CoA sensitivity of the enzymes: insights from expression of chimaeric proteins and mutation of conserved histidine residues.

Authors:  S T Swanson; D W Foster; J D McGarry; N F Brown
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

7.  Propionate-induced changes in cardiac metabolism, notably CoA trapping, are not altered by l-carnitine.

Authors:  Yingxue Wang; Bridgette A Christopher; Kirkland A Wilson; Deborah Muoio; Robert W McGarrah; Henri Brunengraber; Guo-Fang Zhang
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-07-17       Impact factor: 4.310

8.  Carnitine Supplementation Attenuates Sunitinib-Induced Inhibition of AMP-Activated Protein Kinase Downstream Signals in Cardiac Tissues.

Authors:  Mohamed M Sayed-Ahmed; Badr I Alrufaiq; Ammar Alrikabi; Mashan L Abdullah; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Cardiovasc Toxicol       Date:  2019-08       Impact factor: 3.231

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.